Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis
© Berghuis et al; licensee BioMed Central Ltd. 2012
Received: 3 January 2012
Accepted: 8 February 2012
Published: 8 February 2012
Ewing sarcoma patients have a poor prognosis despite multimodal therapy. Integration of combination immunotherapeutic strategies into first-/second-line regimens represents promising treatment options, particularly for patients with intrinsic or acquired resistance to conventional therapies. We evaluated the susceptibility of Ewing sarcoma to natural killer cell-based combination immunotherapy, by assessing the capacity of histone deacetylase inhibitors to improve immune recognition and sensitize for natural killer cell cytotoxicity.
Using flow cytometry, ELISA and immunohistochemistry, expression of natural killer cell receptor ligands was assessed in chemotherapy-sensitive/-resistant Ewing sarcoma cell lines, plasma and tumours. Natural killer cell cytotoxicity was evaluated in Chromium release assays. Using ATM/ATR inhibitor caffeine, the contribution of the DNA damage response pathway to histone deacetylase inhibitor-induced ligand expression was assessed.
Despite comparable expression of natural killer cell receptor ligands, chemotherapy-resistant Ewing sarcoma exhibited reduced susceptibility to resting natural killer cells. Interleukin-15-activation of natural killer cells overcame this reduced sensitivity. Histone deacetylase inhibitor-pretreatment induced NKG2D-ligand expression in an ATM/ATR-dependent manner and sensitized for NKG2D-dependent cytotoxicity (2/4 cell lines). NKG2D-ligands were expressed in vivo, regardless of chemotherapy-response and disease stage. Soluble NKG2D-ligand plasma concentrations did not differ between patients and controls.
Our data provide a rationale for combination immunotherapy involving immune effector and target cell manipulation in first-/second-line treatment regimens for Ewing sarcoma.
KeywordsEwing sarcoma natural killer cells histone deacetylase inhibitor combination immunotherapy chemotherapy-resistance tumour immunology
Ewing sarcoma is an aggressive round cell sarcoma characterized by specific gene fusions most commonly involving TET gene family products, though rarely other activating transcription factors [1–3]. It usually affects bone or soft tissue in children and young adults. Despite multimodal therapy consisting of high-dose chemotherapy, surgery and radiotherapy, survival of patients with Ewing sarcoma has not improved significantly during the past decade. Patients with therapy-resistant or metastatic Ewing sarcoma have the most unfavorable prognosis, with a 5-year overall survival of less than 30% [4–6], which has recently been demonstrated to be independent of Ewing sarcoma-ETS fusion type [4, 5].
Natural killer (NK) cells are the main cytotoxic effector cells of the innate immune system, contributing to host anti-microbial and anti-tumour immune responses. In contrast to T-lymphocytes, these cells lack antigen-specific receptors. Instead, recognition of target cells and subsequent triggering of effector functions is regulated by integration of signals delivered from inhibitory (e.g. killer cell immunoglobulin receptors, CD94/NKG2A) and activating (e.g. natural killer group 2D (NKG2D), DNAX accessory molecule 1 (DNAM1), natural cytotoxicity receptor (NCR)) cell surface receptors [7, 8]. Natural killer cells respond to several cytokines, including several interleukins and type I interferons, resulting in increased cytolytic, secretory and proliferative capacity . Several studies have addressed the therapeutic potential and safety of immunotherapeutic/natural killer cell-based approaches for various cancer types, including sarcomas [10–15]. Sensitivity of tumours to natural killer cells critically depends on expression of ligands for activating receptors. Likewise, low expression of inhibitory human leukocyte antigen (HLA) class I molecules is an important prerequisite for successful natural killer cell triggering. Manipulation of either the balance between activating and inhibitory signals (by, for instance, ex vivo activation of immune cells) and/or sensitization of target cells for immune-mediated killing by combination immunotherapy may improve immunotherapeutic efficacy. For example, pre-conditioning of various cancer cell types by agents that activate the DNA damage response pathway may sensitize for natural killer cell cytotoxicity via induction of activating natural killer cell receptor ligands and/or death receptor expression. Comparable results have been observed for histone deacetylase inhibitors (HDI), which are currently emerging as potent anti-tumour agents [16–19].
Pre-clinical studies show that Ewing sarcoma can be targeted by (cytokine-activated) natural killer cells in a NKG2D-, DNAM1- and, as recently demonstrated, NCR-dependent manner [20–24]. Moreover, a potential role for natural killer cell alloreactivity in Ewing sarcoma disease control has recently been suggested . Integration of natural killer cell-based (combination) immunotherapy into first-line treatment regimens or as a second-line approach represents a promising treatment option for Ewing sarcoma, in particular for patients with either intrinsic or acquired resistance to conventional therapies . However, chemotherapy-resistance of Ewing sarcoma correlates with expression of genes involved in, among others, apoptosis signaling pathways . Depending on the (apoptotic) pathways involved, resistance to apoptosis might render cells cross-resistant to immune cell cytotoxicity . As yet, data about the susceptibility of therapy-resistant Ewing sarcoma to natural killer cell cytotoxicity are lacking. To obtain insight into the potential of natural killer cell-based combination immunotherapy for Ewing sarcoma, natural killer cell receptor ligand expression and susceptibility to natural killer cell cytotoxicity were evaluated in chemotherapy-sensitive and -resistant Ewing sarcoma tumour samples and cell lines respectively. Moreover, since HDI have the ability to exhibit direct cytotoxicity against Ewing sarcoma in vitro as well as in vivo and to sensitize for both conventional and more experimental treatment modalities [29–32], the potential of these agents to sensitize Ewing sarcoma for natural killer cell cytotoxicity was investigated.
Ewing sarcoma patients and samples
Peripheral blood samples from newly diagnosed Ewing sarcoma patients (2004-2009) were collected prior to start of chemotherapy (n = 27) and, in case of complete remission, six months after completion of therapy (n = 7) (treatment according to the EURO-EWING 99 trial ). Samples were centrifuged immediately and plasma was stored at -80°C until assayed. Mean age at diagnosis was 20.8 years (range 4-61 years). Plasma obtained from age-comparable healthy controls (n = 27; mean age 21.8, range 5-65 years) was used as a reference. Formalin-fixed paraffin-embedded, sequential pre-treatment, post-chemotherapy and recurrent metastatic tumour samples (n = 33) from eight Ewing sarcoma patients were obtained from the Department of Pathology, Leiden University Medical Center. In all cases, diagnosis was established according to WHO criteria including standard confirmatory immunohistochemistry and fusion transcript type. Follow-up provided information concerning initial tumour stage, (histological) chemotherapy response , recurrence rate and performance state. All patient material was coded, such that correlation with clinical data was only possible for physicians involved in treatment of the patients. Subsequent research was conducted following the ethical guidelines of the Dutch organization of scientific societies (FEDERA).
Ewing sarcoma cell lines
Ewing sarcoma cell lines SK-ES-1, SK-N-MC, CADO-ES and STA-ET2.1  were cultured in RPMI-1640 supplemented with streptomycin/penicillin (Invitrogen, Paisley, United Kingdom) and 10% fetal bovine serum ((FBS); Greiner Bio-One, Alphen a/d Rijn, The Netherlands). TC71  and IOR/BER (kindly provided by dr. K. Scotlandi, Instituto Orthopedico Rizzoli, Bologna, Italy) were cultured in Iscove's Modified Dulbecco's Medium supplemented with streptomycin/penicillin and 10% FBS. Previously reported [27, 35] 'natural' sensitivity of these cell lines to chemotherapeutic drugs currently used for treatment of Ewing sarcoma  was used to discriminate chemotherapy-sensitive (TC71, SK-ES-1, SK-N-MC) from chemotherapy-resistant (STA-ET2.1, CADO-ES, IOR/BER) cell lines. Molecular HLA typing of the cell lines, performed at Leiden University Medical Center (LUMC), was converted to serological equivalents (no serological equivalents exist for HLA-Cw*16 and -Cw*12): SK-ES-1 (A2/A11/B7/B44/Cw5/Cw7), SK-N-MC (A1/A25/B8/Cw7), CADO-ES (A11/A24/B15/B40/Cw4/Cw7), STA-ET-2.1 (A11/A24/B18/B40/Cw2/Cw5), TC71 (A2/A68/B15/B44/Cw3/Cw5), IOR/BER (A2/A11/B18/B51/Cw7/Cw15). The EBV B-LCL 107 cell line was generated from a healthy blood bank donor expressing HLA alleles which are ligands to all inhibitory killer cell immunoglobulin receptors . The human erythroleukemia cell line K562 was obtained from American Type Culture Collection (Manassas, VA). Cell lines were routinely screened for mycoplasma contamination. Periodical authentication was performed by Short Tandem Repeat profiling and molecular HLA typing.
Antibodies and reagents
The antibodies used for staining of antigens by flow cytometry and immunohistochemistry as well as for blocking of specific natural killer cell receptors and detection of soluble protein by ELISA are described in additional file 1, table S1. HDI [N-(2-amino-phenyl)-4-[N-(pyridine-3-ylmethoxycarbonyl)aminomethyl]benzamide] (MS-275) and suberoylanilide hydroxamic acid (SAHA) were purchased from Enzo Life Sciences (Raamsdonksveer, The Netherlands). Sodium butyrate (NaB) and the pharmacological ATM/ATR inhibitor caffeine were obtained from Sigma-Aldrich (Zwijndrecht, The Netherlands).
Flow cytometric analysis of antigen surface expression
Flow cytometric analysis was performed on a FACScalibur (Beckton Dickinson, Franklin Lakes, NJ) and results were analyzed using Cellquest software, as previously described . Ligand expression was represented as fold increase in Mean Fluorescence Intensity (MFI) over isotype control staining (MFI-ratio).
Immunohistochemistry for detection of NKG2D ligand expression in Ewing sarcoma tumour samples
4-μm sections containing representative tumour were deparaffinized and citrate antigen retrieval was performed. Subsequent immunohistochemical stainings were performed and (semi-quantitatively) scored as previously described .
Quantification of soluble MICA in Ewing sarcoma patient plasma samples
Concentrations of soluble MICA in plasma samples were determined by sandwich-ELISA using the MICA (human) detection set, according to the manufacturer's protocol (BAMOMAB/Axxora, Lörrach, Germany). In short, plates were coated overnight at 4°C with 5 μg/ml of the anti-MICA antibody (AMO1). After blocking with 15% BSA/PBS for 15 minutes at 37°C, plates were washed with 0.05% Tween-20/PBS. Samples or recombinant MICA*04, serving as a standard, were added in 7.5% BSA/PBS. After incubation for two hours at 37°C and washing, detection antibody (anti-MICA/B (BAMO3)) was added at a concentration of 1 μg/ml (two hours, 37°C). Plates were washed and incubated with HRP-conjugated anti-mouse IgG2a antibody (1080-05; SouthernBiotech, Birmingham, AL) for one hour at 37°C. After extensive washing, TMB peroxidase substrate (KPL, Gaithersburg, MD) was added and plates were incubated for 35 minutes at room temperature in the dark. HRP activity was stopped by addition of 1 M phosphoric acid and absorbance was measured at 450 nm wavelength.
Isolation of natural killer cells from healthy donor-derived peripheral blood mononuclear cells
Peripheral blood mononuclear cells were obtained from healthy blood bank donors after informed consent and were isolated using Ficoll density gradient separation. Isolation of natural killer cells was performed using the MACS NK enrichment kit and LS columns, according to the manufacturer's protocol (Miltenyi Biotec, Bergisch Gladbach, Germany) and isolated cells were plated for overnight recovery at 1-2 × 106 cells/ml in RPMI-1640 supplemented with streptomycin/penicillin and 10% FBS. As determined by flow cytometric analysis, natural killer cell purity always exceeded 88% and T-cell contamination > 0.2% was never detected. For cytokine activation, natural killer cells were cultured in AIM-V medium (Invitrogen), supplemented with 10% pooled human AB-serum (Sanquin, Rotterdam, The Netherlands) and streptomycin/penicillin and stimulated with 10 ng/ml recombinant human interleukin-15 (IL-15) (Bender Medical Systems, Vienna, Austria). Activated natural killer cells were used for Chromium (51Cr) release assays within two-four weeks of culture.
Evaluation of natural killer cell cytotoxicity by Chromium release assays
Cytotoxicity was determined in standard 4-hour 51Cr release assays as previously described . For specific natural killer cell receptor (ligand) blocking, natural killer cells or target cells were pre-incubated with blocking antibodies (20 μg/ml; additional file 1, table S1) at room temperature for 20 minutes prior to the 51Cr release assay. We previously demonstrated that pre-incubation of natural killer cells with control isotype (IgG1)-matched antibody (anti-CD56) did not affect cytotoxicity . Moreover, pre-incubation of Ewing sarcoma cells with control isotype (IgG1)-matched antibody (anti-CD99; clone B-N24; Diaclone/Sanquin Reagents, Amsterdam, Netherlands) had no effect on natural killer cell-mediated cytolysis (data not shown).
Pre-treatment of Ewing sarcoma cell lines with histone deacetylase inhibitors
In vitro cytotoxicity (IC50 values) of histone deacetylase inhibitors to chemo-sensitive and -resistant EWS cell linesa
Statistical analyses and artwork
Statistical analyses were performed with SPSS version 16.0 software package. (Paired) t-tests or one-way ANOVA tests were used for comparison of means within or between samples or groups of samples. P < 0.05 was considered statistically significant. Artwork was created using Graphpad Prism 5.0 (La Jolla, CA).
Chemotherapy-resistant Ewing sarcoma exhibit reduced susceptibility to lysis by resting natural killer cells
Comparable expression of ligands for activating and inhibitory natural killer cell receptors in chemotherapy-sensitive and -resistant Ewing sarcoma
In vivo NKG2D ligand expression in sequential Ewing sarcoma tumour samples
sample type (years after diagnosis)
lung metastasis (2)
mediastinal metastasis (3)
lung metastasis (5)
lymph node metastasis (9)
lung metastasis (3)
lung metastasis (4)
bone metastasis (1)
lung metastasis (1)
lung metastasis (0.5)
lung metastasis (2.5)
lung metastasis (3)
bone metastasis (3)
lung metastasis (1.5)
bone metastasis (2.5)
lung metastasis (4)
lung metastasis (4)
lung metastasis (5)
paravertebral metastasis (5)
lung metastasis (8)
MICA plasma levels are not elevated in Ewing sarcoma patients
Shedding of NKG2D ligands, in particular MICA, from the cell surface represents a mechanism by which tumours escape NKG2D immune surveillance [37–39]. Therefore, and based on the in situ expression of MICA in Ewing sarcoma tumours, soluble MICA expression levels were measured in plasma samples from Ewing sarcoma patients. Results were compared to those obtained in plasma samples from age-comparable healthy controls. The majority of plasma samples from healthy controls contained levels of soluble MICA close to the lower detection limit (10 pg/ml) of the assay (median 10 pg/ml; mean 39.63 pg/ml). Plasma concentrations of soluble MICA in patients prior to treatment (median 10 pg/ml; mean 17.67 pg/ml) or after completion of therapy (median 10 pg/ml; mean 25.14 pg/ml) did not significantly differ from those observed in healthy controls (one-way ANOVA, p > 0.05) (Figure 2E).
Chemotherapy-sensitive and -resistant Ewing sarcoma demonstrate comparable susceptibility to IL-15-activated natural killer cells
Histone deacetylase inhibitors induce NKG2D ligand expression in Ewing sarcoma in an ATM/ATR-dependent manner
To assess the capacity of HDI to sensitize Ewing sarcoma for immune-mediated cytotoxicity, cell lines were exposed for 24 hours to HDI belonging to three different structural classes: hydroxamic acid SAHA, short-chain fatty acid NaB and benzamide MS-275. Analysis of the direct cytotoxic effects of these drugs by cell viability assays revealed variation in the sensitivity of the different cell lines to these agents, as represented by variances in drug-specific IC50 values (table 1).
In addition to a direct epigenetic effect resulting in increased expression of target genes, HDI may induce activation of the ATM/ATR-mediated DNA damage response which, in turn, induces NKG2D ligand expression . To assess whether the ATM/ATR response pathway contributed to HDI-induced expression of NKG2D ligands in Ewing sarcoma cells, cell lines were treated with ATM/ATR inhibitor caffeine (5 mM) for 2 hours prior to incubation with these agents. Indeed, caffeine pre-treatment largely prevented HDI-mediated induction of NKG2D ligands, but not HLA class I, in all cell lines (as exemplified for MICB/HLA class I expression upon MS-275 in Figure 4E).
Histone deacetylase inhibitors sensitize Ewing sarcoma for NKG2D-dependent natural killer cell cytotoxicity
To assess the functional relevance of HDI-induced alterations in natural killer cell receptor ligand expression, HDI pre-treated Ewing sarcoma cells were subjected to 51Cr release assays using resting natural killer cells. Pre-treatment of the chemotherapy-resistant CADO-ES cell line with HDI NaB, MS-275 and SAHA sensitized, in a dose-dependent manner, for natural killer cell cytotoxicity (as shown for NaB in Figure 4F; paired t-test (medium versus 1/20 of IC50 value), p < 0.05 at effector-to-target ratio's ≥ 5:1). Similarly, pre-treatment of SK-ES-1 cells with SAHA (1/5 of IC50 value), but not NaB or MS-275, resulted in significantly increased cytolysis (data not shown). In cell lines TC71 and STA-ET2.1, despite induction of activating NKG2D ligands, no sensitization for natural killer cell cytotoxicity was detectable (additional file 4, figure S3A). The role of NKG2D in natural killer cell recognition and cytolysis of HDI-treated Ewing sarcoma cells was evaluated by performing 51Cr release assays in the presence of a blocking antibody against NKG2D. In both CADO-ES and SK-ES-1 cells, these experiments revealed (persistent) dependence on signaling via this activating natural killer cell receptor since blocking reduced lysis of both untreated and HDI-treated cells (as demonstrated for CADO-ES upon NaB in additional file 4, figure S3B).
Despite current multimodal therapy consisting of high-dose chemotherapy, surgery and radiotherapy, survival of patients with Ewing sarcoma has not improved during the past decade. Integration of natural killer cell-based combination immunotherapy into first-line treatment regimens or as a second-line approach, as recently emphasized by Ahn et al. , represents a promising treatment option for Ewing sarcoma, in particular for patients with either intrinsic or acquired therapy-resistance. Current immunotherapeutic strategies presume therapy-resistant tumours to be sensitive to immune-mediated cytotoxicity. However, depending on the pathways involved, resistance to conventional therapies might render cells cross-resistant to immunotherapy . The observed reduced susceptibility of chemotherapy-resistant Ewing sarcoma to resting natural killer cell cytotoxicity might be indicative for the existence of cross-resistance mechanisms.
Resistance of Ewing sarcoma to chemotherapy correlates (inversely) with differential expression of genes involved in apoptosis, including caspase-8 and p53 pathways [27, 40, 41]. Based on available data about caspase-8 expression and p53 mutation status in our panel of cell lines [27, 34, 36, 42–44], however, the observed cross-resistance to resting natural killer cells cannot be explained by aberrant expression or the mutation status of these proteins alone. P-glycoprotein is a drug-efflux pump that confers multidrug resistance to a wide range of chemotherapeutic drugs, including key chemotherapeutic agents used for Ewing sarcoma treatment [4, 45]. In addition to its ability to efflux drugs, P-glycoprotein regulates apoptosis by inhibition of caspase activation . Theoretically, P-glycoprotein expression in our panel of cell lines might contribute to the observed (relative) cross-resistance to natural killer cells [47, 48]. However, whereas caspase-dependent apoptosis is prevented, P-glycoprotein expressing cells remain sensitive to perforin/granzyme B-induced cell death . We previously demonstrated natural killer cell-mediated apoptosis induction in Ewing sarcoma cells to be largely dependent on the perforin/granzyme B-mediated granule exocytosis pathway rather than on caspase-dependent death receptor pathways . Therefore, we assume P-glycoprotein expression a non-crucial factor in cross-resistance of Ewing sarcoma to immune-mediated cytotoxicity. Since susceptibility of Ewing sarcoma to natural killer cell-mediated lysis depends on expression of ligands for activating and inhibitory natural killer cell receptors [20, 23, 24], differential expression of these ligands among chemotherapy-sensitive and -resistant cells could be an alternative explanation for the observed chemo-/immunotherapy cross-resistance of Ewing sarcoma. Considerable inter-cell line variation was observed for HLA class I expression, with a 50-fold increased expression in chemotherapy- and natural killer cell-resistant CADO-ES cells as compared to chemotherapy-/natural killer cell-sensitive SK-ES-1 cells. In a recent report, Holmes et al.  point to the existence of natural killer cell activation/inhibition thresholds that allow small changes in HLA class I cell surface expression to dramatically alter susceptibility of Ewing sarcoma to natural killer cells. However, no significant effects of HLA class I blocking were observed (current and previous studies ), excluding a major contribution of dominant inhibitory signals provided by (differential) HLA class I expression. Moreover, and in addition to the observed comparable constitutive expression of activating NKG2D and DNAM1-ligands, blocking of NKG2D and DNAM1 on resting natural killer cells reduced natural killer cell-mediated cytolysis of both chemotherapy-sensitive and -resistant cells to a similar degree. Together, our results point to the existence of true cross-resistance to immune-mediated cytolysis rather than to dissimilar expression of activating/inhibitory natural killer cell receptor ligands or differential dependency on signaling via activating receptors NKG2D and DNAM1. As yet, since ligands for activating NCR are largely unknown [7, 24, 49], a possible contribution of such ligand can not be excluded. Similary, other possible causes for cross-resistance to conventional and immunotherapeutic approaches in Ewing sarcoma, that have not been addressed (e.g. (over)expression of (other) pro- or anti-apoptotic factors  or dysregulation of specific signaling pathways ), may need further investigation.
Importantly, the relative resistance of chemotherapy-resistant Ewing sarcoma cells to lysis by resting natural killer cells could be overcome by pre-activation of natural killer cells with IL-15. Although the exact mechanisms underlying cross-resistance to chemotherapeutic drugs and immune-mediated cytotoxicity have not been fully elucidated, utilization of complementary (apoptotic) pathways or stronger pro-apoptotic signals by cytokine-activated natural killer cells  may contribute to the observed increased cytotoxic potential of these cells toward (chemotherapy-resistant) Ewing sarcoma. Irrespective of the exact mechanism, however, the observation that chemotherapy-resistant Ewing sarcoma do not exhibit cross-resistance to IL-15-activated natural killer cell-mediated immunotherapy suggests that cytokine-activated natural killer cell therapies may represent promising immunotherapeutic options for patients with Ewing sarcoma.
Due to the nature of this (bone) tumour, attempts to establish primary tumour cell cultures from therapy-naive biopsies for evaluation of natural killer cell cytotoxicity towards these targets have so far been unsuccessful. Support for potential in vivo immune recognition of Ewing sarcoma tumours, however, was provided by immunohistochemical analysis of sequential Ewing sarcoma tumour samples demonstrating expression of (at least one of the) activating natural killer cell receptor ligands MICA and ULBP1 throughout all stages of disease and regardless of the histological response to chemotherapy. Moreover, and similar to previous observations in leukemia , a potential role for natural killer cell alloreactivity in Ewing sarcoma disease control has been suggested . In addition to recognition by natural killer cells, expression of NKG2D ligands might improve anti-tumour immune responses by specific T-lymphocyte subsets . We recently reported on the (prognostically beneficial) impact of tumour-infiltrating T-lymphocytes on tumour progression in therapy-naive Ewing sarcoma . Despite in situ expression of NKG2D ligands, tumour cells may escape from NKG2D immunosurveillance by (enhanced) shedding of these ligands from their cell surfaces. Subsequently, circulating tumour-derived soluble ligands may cause downregulation of NKG2D and, in turn, severely impair cytotoxic effector functions of both T- and natural killer cells [37–39]. Based on our current results demonstrating non-elevated soluble MICA levels in plasma of Ewing sarcoma patients (as compared to age-comparable healthy controls) as well as our previous observation of intact NKG2D expression on natural killer cells of these patients , we do not consider NKG2D ligand shedding a relevant immune escape mechanism in patients with this tumour. We previously reported on reduced levels of HLA class I expression in advanced-stage Ewing sarcoma as a potential immune escape mechanism hampering recognition by tumour-reactive T-lymphocytes and feasibility of T cell-based immunotherapeutic approaches . Our current observations of 1) in situ expression of ligands for activating natural killer cell receptors throughout all stages of disease, including (chemotherapy-resistant) metastatic disease, 2) the absence of (enhanced) shedding of these activating natural killer cell receptor ligands, 3) the above mentioned reduced expression of inhibitory HLA class I molecules in advanced-stage Ewing sarcoma cases and 4) the observed susceptibility of (chemotherapy-resistant) Ewing sarcoma to IL-15-activated natural killer cells further support the potential of Ewing sarcoma as an attractive target for natural killer cell-based immunotherapy.
Several phase I-III clinical trials now prove HDI-treatment to be safe and effective in both hematological and solid tumours (as reviewed by ) and recently, different HDI were approved by the US Food and Drug Administration for use in patients . With regard to Ewing sarcoma, a role for HDI in reversal of oncogenic transcriptional repression has been proposed . In addition, HDI-mediated cytotoxicity has been demonstrated both in vitro and in vivo and sensitization for both conventional and more experimental treatment modalities has been suggested [29, 31, 32]. Here, we demonstrate the ability of three structurally different HDI to, at doses 5-20 times lower than the established IC50 values, improve potential immune recognition (by natural killer cells and/or specific T-lymphocyte subsets) of both chemotherapy-sensitive and -resistant Ewing sarcoma. HDI-pretreatment resulted in ATM/ATR-dependent induction of NKG2D ligands, in particular MICA and MICB, in all cell lines. Moreover, dose-dependent sensitization for natural killer cell cytotoxicity was observed in 2/4 cell lines, including the chemotherapy-resistant CADO-ES cell line. The doses used in vitro were below or within the range of the maximum tolerated dose as determined in recent clinical trials (in children) [59, 60]. Natural killer cell cytotoxicity depended on NKG2D-NKG2D ligand interactions, since blocking of NKG2D abrogated cytolysis. No sensitization was observed for TC71 and STA-ET2.1 cells, despite induction of NKG2D ligands. As yet, an adequate explanation for this observation is lacking. Although HDI-pretreatment induced HLA class I in these cell lines, a contribution of dominant inhibitory signals provided by this increased expression seems unlikely since HLA class I blocking did not significantly affect natural killer cell-mediated cytolysis.
Collectively, our data provide a rationale for combination immunotherapy involving immune effector cell (IL-15-activated natural killer cells) and target cell (HDI) manipulation in first- and/or second-line treatment regimens for Ewing sarcoma.
Patients with Ewing sarcoma (EWS) have a poor prognosis, despite current multimodal therapy. Integration of immunotherapeutic strategies, including natural killer (NK) cell-based therapies, into first-line treatment regimens or introduction of these approaches as second-line therapy may represent promising treatment options. Ex vivo immune cell activation and/or (simultaneous) sensitization of target cells for immune-mediated killing by combination immunotherapy may overcome intrinsic/acquired resistance to conventional therapies and improve (immuno)therapeutic efficacy. Here, we provide the first evidence that combination immunotherapy using histone deacetylase inhibitors and (interleukin-15-activated) NK cells improves immune recognition of both therapy-sensitive and -resistant EWS and sensitizes for NK cell cytotoxicity. In vivo expression of activating NK cell receptor ligands throughout all disease-stages, regardless of chemotherapy-response, supports their potential in vivo role in immune recognition of EWS. Our data provide a rationale for combination immunotherapy involving simultaneous immune cell (interleukin-15-activated NK cells) and target cell (histone deacetylase inhibitors) manipulation in first-/second-line treatment regimens for EWS.
The authors thank Jurre van Kesteren, Monique M. van Ostaijen-ten Dam, S. Eriaty N. Ruslan (Department of Pediatrics, Leiden University Medical Center (LUMC), The Netherlands) and M.J. Ronkes for technical assistance; Katia Scotlandi (Instituto Orthopedico Rizzoli, Bologna, Italy) for provision of Ewing sarcoma cell line IOR/BER; Maarten J.D. van Tol (Department of Pediatrics, LUMC), H. Gelderblom (Department of Clinical Oncology, LUMC) and A.H.M. Taminiau (Department of Orthopedic Surgery, LUMC) for provision of plasma and tumour samples respectively. Grant support: European Commission (EuroBoNeT, grant no. 018814 (P.C.W.H.)); Foundation 'The Quality of Life Gala 2007' (A.C.L.); Dutch Cancer Society (grant RUL 2003-2800 (A.C.L. and P.C.W.H.)).
- Riggi N, Cironi L, Suva ML, Stamenkovic I: Sarcomas: genetics, signalling, and cellular origins. Part 1: The fellowship of TET. J Pathol. 2007, 213: 4-20. 10.1002/path.2209View ArticlePubMedGoogle Scholar
- Szuhai K, Ijszenga M, de Jong D, Karseladze A, Tanke HJ, Hogendoorn PCW: The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin Cancer Res. 2009, 15: 2259-2268. 10.1158/1078-0432.CCR-08-2184View ArticlePubMedGoogle Scholar
- Ushigome S, Machinami R, Sorensen PH: Ewing Sarcoma/Primitive Neuroectodermal Tumour. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft tissue and Bone. Edited by: Fletcher CDM, Unni KK, Mertens F. 2002, 298-300. Lyon: IARC Press,Google Scholar
- Juergens C, Weston C, Lewis I, Whelan J, Paulussen M, Oberlin O, Michon J, Zoubek A, Juergens H, Craft A: Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer. 2006, 47: 22-29. 10.1002/pbc.20820View ArticlePubMedGoogle Scholar
- Le Deley MC, Delattre O, Schaefer KL, Burchill SA, Koehler G, Hogendoorn PCW, Lion T, Poremba C, Marandet J, Ballet S, Pierron G, Brownhill SC, Nesslbock M, Ranft A, Dirksen U, Oberlin O, Lewis IJ, Craft AW, Jurgens H, Kovar H: Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol. 2010, 28: 1982-1988. 10.1200/JCO.2009.23.3585View ArticlePubMedGoogle Scholar
- van Doorninck JA, Ji L, Schaub B, Shimada H, Wing MR, Krailo MD, Lessnick SL, Marina N, Triche TJ, Sposto R, Womer RB, Lawlor ER: Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2010, 28: 1989-1994. 10.1200/JCO.2009.24.5845PubMed CentralView ArticlePubMedGoogle Scholar
- Moretta L, Moretta A: Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 2004, 23: 255-259. 10.1038/sj.emboj.7600019PubMed CentralView ArticlePubMedGoogle Scholar
- Cerwenka A, Lanier LL: Natural killer cells, viruses and cancer. Nat Rev Immunol. 2001, 1: 41-49. 10.1038/35095564View ArticlePubMedGoogle Scholar
- Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP: Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol. 1999, 17: 189-220. 10.1146/annurev.immunol.17.1.189View ArticlePubMedGoogle Scholar
- Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002, 295: 2097-2100. 10.1126/science.1068440View ArticlePubMedGoogle Scholar
- Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB: Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005, 105: 3051-3057. 10.1182/blood-2004-07-2974View ArticlePubMedGoogle Scholar
- Klingemann HG: Natural killer cell-based immunotherapeutic strategies. Cytotherapy. 2005, 7: 16-22. 10.1080/14653240510018000View ArticlePubMedGoogle Scholar
- Ljunggren HG, Malmberg KJ: Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 2007, 7: 329-339. 10.1038/nri2073View ArticlePubMedGoogle Scholar
- Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, Kleinerman E, Link MP, Nadel H, Nieder M, Siegal GP, Weiner MA, Wells RJ, Womer RB, Grier HE: Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol. 2008, 26: 633-638. 10.1200/JCO.2008.14.0095View ArticlePubMedGoogle Scholar
- Whelan J, Patterson D, Perisoglou M, Bielack S, Marina N, Smeland S, Bernstein M: The role of interferons in the treatment of osteosarcoma. Pediatr Blood Cancer. 2010, 54: 350-354. 10.1002/pbc.22136View ArticlePubMedGoogle Scholar
- Gasser S, Orsulic S, Brown EJ, Raulet DH: The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005, 436: 1186-1190. 10.1038/nature03884PubMed CentralView ArticlePubMedGoogle Scholar
- Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, Odum N: Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 2005, 65: 11136-11145. 10.1158/0008-5472.CAN-05-0599View ArticlePubMedGoogle Scholar
- Schmudde M, Braun A, Pende D, Sonnemann J, Klier U, Beck JF, Moretta L, Broker BM: Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. Cancer Lett. 2008, 272: 110-121. 10.1016/j.canlet.2008.06.027View ArticlePubMedGoogle Scholar
- Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di G, Cippitelli M, Fionda C, Petrucci MT, Guarini A, Foa R, Santoni A: ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood. 2009, 113: 3503-3511. 10.1182/blood-2008-08-173914View ArticlePubMedGoogle Scholar
- Verhoeven DH, de Hooge AS, Mooiman EC, Santos SJ, ten Dam MM, Gelderblom H, Melief CJ, Hogendoorn PCW, Egeler RM, van Tol MJ, Schilham MW, Lankester AC: NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol. 2008, 45: 3917-3925. 10.1016/j.molimm.2008.06.016View ArticlePubMedGoogle Scholar
- Staege MS, Hansen G, Baersch G, Burdach S: Functional and molecular characterization of interleukin-2 transgenic Ewing tumor cells for in vivo immunotherapy. Pediatr Blood Cancer. 2004, 43: 23-34. 10.1002/pbc.20013View ArticlePubMedGoogle Scholar
- Atzpodien J, Gulati SC, Shimazaki C, Buhrer C, Oz S, Kwon JH, Kolitz JE, Clarkson BD: Ewing's sarcoma: ex vivo sensitivity towards natural and lymphokine-activated killing. Oncology. 1988, 45: 437-443. 10.1159/000226661View ArticlePubMedGoogle Scholar
- Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D: Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res. 2010, 16: 3901-3909. 10.1158/1078-0432.CCR-10-0735PubMed CentralView ArticlePubMedGoogle Scholar
- Holmes TD, El-Sherbiny YM, Davison A, Clough SL, Blair GE, Cook GP: A human NK cell activation/inhibition threshold allows small changes in the target cell surface phenotype to dramatically alter susceptibility to NK cells. J Immunol. 2011, 186: 1538-1545. 10.4049/jimmunol.1000951View ArticlePubMedGoogle Scholar
- Perez-Martinez A, Leung W, Munoz E, Iyengar R, Ramirez M, Vicario JL, Lassaletta A, Sevilla J, Gonzalez-Vicent M, Madero L, Diaz-Perez MA: KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. Pediatr Blood Cancer. 2009, 53: 120-124. 10.1002/pbc.21955View ArticlePubMedGoogle Scholar
- Ahn YO, Weigel B, Verneris MR: Killing the killer: natural killer cells to treat Ewing's sarcoma. Clin Cancer Res. 2010, 16: 3819-3821. 10.1158/1078-0432.CCR-10-1368View ArticlePubMedGoogle Scholar
- Schaefer KL, Eisenacher M, Braun Y, Brachwitz K, Wai DH, Dirksen U, Lanvers-Kaminsky C, Juergens H, Herrero D, Stegmaier S, Koscielniak E, Eggert A, Nathrath M, Gosheger G, Schneider DT, Bury C, Diallo-Danebrock R, Ottaviano L, Gabbert HE, Poremba C: Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer. 2008, 44: 699-709. 10.1016/j.ejca.2008.01.020View ArticlePubMedGoogle Scholar
- Ng CP, Bonavida B: A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance. Adv Cancer Res. 2002, 85: 145-174.View ArticlePubMedGoogle Scholar
- Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R, Bates SE, Thiele CJ: MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res. 2002, 62: 6108-6115.PubMedGoogle Scholar
- Nakatani F, Tanaka K, Sakimura R, Matsumoto Y, Matsunobu T, Li X, Hanada M, Okada T, Iwamoto Y: Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem. 2003, 278: 15105-15115. 10.1074/jbc.M211470200View ArticlePubMedGoogle Scholar
- Sakimura R, Tanaka K, Nakatani F, Matsunobu T, Li X, Hanada M, Okada T, Nakamura T, Matsumoto Y, Iwamoto Y: Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. Int J Cancer. 2005, 116: 784-792. 10.1002/ijc.21069View ArticlePubMedGoogle Scholar
- Sonnemann J, Dreyer L, Hartwig M, Palani CD, Hong lT, Klier U, Broker B, Volker U, Beck JF: Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells. J Cancer Res Clin Oncol. 2007, 133: 847-858. 10.1007/s00432-007-0227-8View ArticlePubMedGoogle Scholar
- van der Woude HJ, Bloem JL, Taminiau AH, Nooy MA, Hogendoorn PCW: Classification of histopathologic changes following chemotherapy in Ewing's sarcoma of bone. Skeletal Radiol. 1994, 23: 501-507.View ArticlePubMedGoogle Scholar
- Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PCW, Buerger H, Aigner T, Gabbert HE, Poremba C: Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer. 2010, 49: 40-51. 10.1002/gcc.20717View ArticlePubMedGoogle Scholar
- Scotlandi K, Perdichizzi S, Manara MC, Serra M, Benini S, Cerisano V, Strammiello R, Mercuri M, Reverter-Branch , Faircloth G, D'Incalci M, Picci P: Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clin Cancer Res. 2002, 8: 3893-3903.PubMedGoogle Scholar
- de Hooge ASK, Berghuis D, Santos SJ, Mooiman E, Romeo S, Kummer JA, Egeler RM, van Tol MJ, Melief CJ, Hogendoorn PCW, Lankester AC: Expression of cellular FLICE inhibitory protein, caspase-8, and protease inhibitor-9 in Ewing sarcoma and implications for susceptibility to cytotoxic pathways. Clin Cancer Res. 2007, 13: 206-214. 10.1158/1078-0432.CCR-06-1457View ArticlePubMedGoogle Scholar
- Groh V, Wu J, Yee C, Spies T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002, 419: 734-738. 10.1038/nature01112View ArticlePubMedGoogle Scholar
- Raffaghello L, Prigione I, Airoldi I, Camoriano M, Levreri I, Gambini C, Pende D, Steinle A, Ferrone S, Pistoia V: Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia. 2004, 6: 558-568. 10.1593/neo.04316PubMed CentralView ArticlePubMedGoogle Scholar
- Salih HR, Holdenrieder S, Steinle A: Soluble NKG2D ligands: prevalence, release, and functional impact. Front Biosci. 2008, 13: 3448-3456.View ArticlePubMedGoogle Scholar
- Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, Wexler LH, Gorlick R, Meyers P, Ladanyi M: Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol. 2005, 23: 548-558.View ArticlePubMedGoogle Scholar
- Abudu A, Mangham DC, Reynolds GM, Pynsent PB, Tillman RM, Carter SR, Grimer RJ: Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis. Br J Cancer. 1999, 79: 1185-1189. 10.1038/sj.bjc.6690190PubMed CentralView ArticlePubMedGoogle Scholar
- Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM: Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene. 2001, 20: 5865-5877. 10.1038/sj.onc.1204750View ArticlePubMedGoogle Scholar
- Harada K, Toyooka S, Shivapurkar N, Maitra A, Reddy JL, Matta H, Miyajima K, Timmons CF, Tomlinson GE, Mastrangelo D, Hay RJ, Chaudhary PM, Gazdar AF: Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res. 2002, 62: 5897-5901.PubMedGoogle Scholar
- Hotfilder M, Sondermann P, Senss A, van Valen F, Jurgens H, Vormoor J: PI3K/AKT is involved in mediating survival signals that rescue Ewing tumour cells from fibroblast growth factor 2-induced cell death. Br J Cancer. 2005, 92: 705-710. 10.1038/sj.bjc.6602384PubMed CentralView ArticlePubMedGoogle Scholar
- Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM: P-glycoprotein: from genomics to mechanism. Oncogene. 2003, 22: 7468-7485. 10.1038/sj.onc.1206948View ArticlePubMedGoogle Scholar
- Johnstone RW, Cretney E, Smyth MJ: P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood. 1999, 93: 1075-1085.PubMedGoogle Scholar
- Roessner A, Ueda Y, Bockhorn-Dworniczak B, Blasius S, Peters A, Wuisman P, Ritter J, Paulussen M, Jurgens H, Bocker W: Prognostic implication of immunodetection of P glycoprotein in Ewing's sarcoma. J Cancer Res Clin Oncol. 1993, 119: 185-189. 10.1007/BF01624429View ArticlePubMedGoogle Scholar
- Hijazi YM, Axiotis CA, Navarro S, Steinberg SM, Horowitz ME, Tsokos M: Immunohistochemical detection of P-glycoprotein in Ewing's sarcoma and peripheral primitive neuroectodermal tumors before and after chemotherapy. Am J Clin Pathol. 1994, 102: 61-67.PubMedGoogle Scholar
- Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, Haldeman B, Ostrander CD, Kaifu T, Chabannon C, Moretta A, West R, Xu W, Vivier E, Levin SD: The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med. 2009, 206: 1495-1503. 10.1084/jem.20090681PubMed CentralView ArticlePubMedGoogle Scholar
- Tirado OM, MacCarthy CM, Fatima N, Villar J, Mateo-Lozano S, Notario V: Caveolin-1 promotes resistance to chemotherapy-induced apoptosis in Ewing's sarcoma cells by modulating PKCalpha phosphorylation. Int J Cancer. 2010, 126: 426-436. 10.1002/ijc.24754PubMed CentralView ArticlePubMedGoogle Scholar
- Saudemont A, Hamrouni A, Marchetti P, Liu J, Jouy N, Hetuin D, Colucci F, Quesnel B: Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling. Cancer Res. 2007, 67: 4491-4498. 10.1158/0008-5472.CAN-06-1627View ArticlePubMedGoogle Scholar
- Zhang C, Zhang J, Niu J, Zhang J, Tian Z: Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation. Cytokine. 2008, 42: 128-136. 10.1016/j.cyto.2008.01.003View ArticlePubMedGoogle Scholar
- Champsaur M, Lanier LL: Effect of NKG2D ligand expression on host immune responses. Immunol Rev. 2010, 235: 267-285.PubMed CentralPubMedGoogle Scholar
- Berghuis D, Santos SJ, Baelde HJ, Taminiau AH, Egeler RM, Schilham MW, Hogendoorn PCW, Lankester AC: Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. J Pathol. 2011, 223: 347-357. 10.1002/path.2819View ArticlePubMedGoogle Scholar
- Berghuis D, de Hooge AS, Santos SJ, Horst D, Wiertz EJ, Van Eggermond MC, van den Elsen PJ, Taminiau AH, Ottaviano L, Schaefer KL, Dirksen U, Hooijberg E, Mulder A, Melief CJ, Egeler RM, Schilham MW, Jordanova ES, Hogendoorn PCW, Lankester AC: Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J Pathol. 2009, 218: 222-231. 10.1002/path.2537View ArticlePubMedGoogle Scholar
- Tan J, Cang S, Ma Y, Petrillo RL, Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010, 3: 5- 10.1186/1756-8722-3-5PubMed CentralView ArticlePubMedGoogle Scholar
- StatBite: FDA oncology drug product approvals in 2009. J Natl Cancer Inst. 2010, 102: 219-
- Owen LA, Kowalewski AA, Lessnick SL: EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. PLoS One. 2008, 3: e1965- 10.1371/journal.pone.0001965PubMed CentralView ArticlePubMedGoogle Scholar
- Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J, Reid JM, Ames MM, Speights R, Ingle AM, Zwiebel J, Blaney SM, Adamson PC: Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol. 2010, 28: 3623-3629. 10.1200/JCO.2009.25.9119PubMed CentralView ArticlePubMedGoogle Scholar
- Tan J, Cang S, Ma Y, Petrillo RL, Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010, 3: 5- 10.1186/1756-8722-3-5PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.